PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.


Matthew S. Davids, MD, MMSc - Pushing Therapeutic Boundaries in CLL: The Convergence of Targeted Therapy, Novel Combinations, and Precision Medicine in Patient Care

Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populations. Our expert panel explores important topics such as optimal treatment of poor-risk and good-risk CLL, therapeutic sequencing, safety management and distinctions among agent classes, and the future of novel combinations in patient care. Upon completion of this accredited CE activity, participants should be better able to: Identify relevant prognostic factors, genetic/molecular findings, and patient- or disease-related features that influence modern treatment selection in chronic lymphocytic leukemia (CLL), Summarize updated efficacy and safety findings surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, or BCL-2 inhibitors; novel combinations; and strategies producing minimal residual disease–negative responses, Select optimized treatment with targeted agents, including fixed duration or continuous therapy, or appropriate combinational or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.


 2021-07-16  1h29m